Acticor Biotech launches a capital increase of 3 million euros – 11/27/2023 at 6:15 p.m.

(AOF) – Acticor Biotech announces the launch of a capital increase of approximately 3 million euros via the issue of new ordinary shares aimed at institutional and individual investors. The company which is developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, specifies that the objective is to register this product in the emergency treatment of stroke. This involves financing the continuation of the Actisave study until the results expected in the second quarter of 2024.

According to Acticor, the funds raised will allow it to strengthen its financial structure and finance its operations until June 2024, while its level of cash and net cash equivalents stood at 7.95 as of June 30, 2023. millions of euros.

The Company’s financing requirement to meet its obligations over the next 12 months is estimated by the Company at approximately 7.5 million euros: Acticor therefore announces that it will have to “seek other sources of debt financing or in equity” or “carry out partnership or M&A transactions” from the first quarter of 2024, in order to supplement its working capital needs and finance its operating expenses beyond the second quarter of 2024.


Learn more about the Pharmacy sector

Oncology, priority of pharmaceutical giants

Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.

Source link -86